According to Quintiles, the new facility has been constructed jointly with Apollo Hospitals Group and offers biopharma customers additional options to complete integrated Phase I programs across multiple geographies at this pivotal stage in medical research.
The new facility houses 86 beds, out of which 32 beds are equipped with diagnostic cardiology equipment for TQT studies.
The new Hyderabad facility is expected to assess compounds developed both in India and in other countries.
Data capture will be linked electronically to Quintiles other Phase I units in the UK, the US and Sweden.